Market Overview

UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong Antibiotic Portfolio

Related CBST
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog

In a report published Thursday, Oppenheimer analyst Akiva Felt initiated coverage on Cubist Pharmaceuticals (NASDAQ: CBST) with an Outperform rating and $81.00 price target.

In the report, Oppenheimer noted, “Cubist develops acute care drugs for the hospital setting, with an emphasis on antibiotics. We recommend exposure to antibiotics due to the ongoing emergence of multiple-drug-resistant (MDR) infections, which maintain significant unmet medical needs and prevent the landscape from falling entirely to generic drugs. Cubist's broad antibiotic portfolio addresses key unmet needs, and its R&D platform should help maintain a thriving pipeline. Our bullish stance stems from CXA-201 in Phase 3 studies to treat gram-negative infections, with data expected in 4Q13. If it is approved, we expect peak CXA-201 sales to eclipse Cubicin. Moreover, we think CBST shares will benefit from increased M&A activity in biotech, as CXA-201 approval should lead to increased takeout speculation.”

Cubist Pharmaceuticals closed on Wednesday at $63.65.

Posted-In: Akiva Felt OppenheimerAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (CBST)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free